Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT03920852
- Locations
- 🇺🇸
Orange County Research Center, Anaheim, California, United States
🇺🇸San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States
🇺🇸RM Medical Research, INC., Miami, Florida, United States
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
- Conditions
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03920839
Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
- Conditions
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03906318
Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03906344
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03906357
Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03896815
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 15
- Registration Number
- NCT03837509
- Locations
- 🇺🇸
New York Oncology Hematology, Albany, New York, United States
🇺🇸Virginia Cancer Specialists-Fairfax, Fairfax, Virginia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 111
- Registration Number
- NCT03822117
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Cancer Treatment Centers of America, Zion, Illinois, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03780166
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 138
- Registration Number
- NCT03762447
- Locations
- 🇫🇷
Icm Montpellier, Montpellier Cedex 5, France
🇫🇷Institut Universitaire Du Cancer de Toulouse Oncopole, Toulouse, France
🇺🇸Jefferson University Hospitals, Philadelphia, Pennsylvania, United States